Opus Genetics (IRD) Competitors $1.20 +0.02 (+1.69%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.20 0.00 (0.00%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD vs. MREO, TLSA, SCPH, IMMP, TKNO, ALMS, FENC, NMRA, GALT, and PBYIShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Mereo BioPharma Group (MREO), Tiziana Life Sciences (TLSA), scPharmaceuticals (SCPH), Prima BioMed (IMMP), Alpha Teknova (TKNO), Alumis (ALMS), Adherex Technologies (FENC), Neumora Therapeutics (NMRA), Galectin Therapeutics (GALT), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Mereo BioPharma Group Tiziana Life Sciences scPharmaceuticals Prima BioMed Alpha Teknova Alumis Adherex Technologies Neumora Therapeutics Galectin Therapeutics Puma Biotechnology Opus Genetics (NASDAQ:IRD) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings. Do analysts rate IRD or MREO? Opus Genetics presently has a consensus price target of $7.33, indicating a potential upside of 511.11%. Mereo BioPharma Group has a consensus price target of $7.20, indicating a potential upside of 313.79%. Given Opus Genetics' higher possible upside, research analysts plainly believe Opus Genetics is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more volatility and risk, IRD or MREO? Opus Genetics has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Which has higher valuation and earnings, IRD or MREO? Mereo BioPharma Group has lower revenue, but higher earnings than Opus Genetics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$15.42M4.64-$57.53M-$1.92-0.63Mereo BioPharma Group$500K553.32-$43.25M-$0.07-24.86 Does the media prefer IRD or MREO? In the previous week, Mereo BioPharma Group had 17 more articles in the media than Opus Genetics. MarketBeat recorded 26 mentions for Mereo BioPharma Group and 9 mentions for Opus Genetics. Mereo BioPharma Group's average media sentiment score of 0.51 beat Opus Genetics' score of 0.24 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is IRD or MREO more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Mereo BioPharma Group's return on equity of -80.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-377.89% -384.33% -148.90% Mereo BioPharma Group N/A -80.00%-66.94% Do insiders & institutionals have more ownership in IRD or MREO? 15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.6% of Opus Genetics shares are owned by insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryMereo BioPharma Group beats Opus Genetics on 13 of the 17 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.40M$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.12%P/E Ratio-0.6320.8931.0825.11Price / Sales4.64366.96467.01193.48Price / CashN/A42.3037.4059.05Price / Book4.148.659.096.18Net Income-$57.53M-$54.65M$3.26B$265.11M7 Day Performance12.15%6.56%7.36%4.21%1 Month Performance7.14%7.53%5.47%2.01%1 Year PerformanceN/A13.69%30.61%23.75% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.8526 of 5 stars$1.20+1.7%$7.33+511.1%N/A$70.40M$15.42M-0.6314News CoverageEarnings ReportGap UpMREOMereo BioPharma Group2.0859 of 5 stars$1.65+8.2%$7.20+337.7%-57.4%$259.97M$10M-23.3640Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionTLSATiziana Life Sciences0.6427 of 5 stars$2.22-9.8%N/A+66.9%$259.41MN/A0.008News CoverageSCPHscPharmaceuticals4.4934 of 5 stars$4.81+3.1%$14.00+191.4%-9.1%$255.84M$36.33M-2.6530News CoverageShort Interest ↓IMMPPrima BioMed1.4576 of 5 stars$1.74+2.1%$7.00+303.5%-20.3%$254.68M$5.14M0.002,021Positive NewsTKNOAlpha Teknova2.3686 of 5 stars$4.73+7.1%$10.00+111.6%+16.7%$253.57M$37.74M-11.30240Gap DownALMSAlumis2.8429 of 5 stars$4.55+4.7%$19.80+335.6%-63.1%$247.29MN/A0.00N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionFENCAdherex Technologies2.3602 of 5 stars$8.87+7.5%$13.00+46.6%+49.8%$245.28M$47.54M-17.2910News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionNMRANeumora Therapeutics2.9482 of 5 stars$1.50+3.8%$7.14+377.8%-86.2%$242.12MN/A-0.95108Positive NewsGALTGalectin Therapeutics2.0644 of 5 stars$3.78-2.7%$6.00+58.9%+63.0%$240.50MN/A-5.289News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionPBYIPuma Biotechnology3.7047 of 5 stars$4.80-1.0%$7.00+45.7%+116.2%$240.42M$230.50M4.87200High Trading Volume Related Companies and Tools Related Companies Mereo BioPharma Group Alternatives Tiziana Life Sciences Alternatives scPharmaceuticals Alternatives Prima BioMed Alternatives Alpha Teknova Alternatives Alumis Alternatives Adherex Technologies Alternatives Neumora Therapeutics Alternatives Galectin Therapeutics Alternatives Puma Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access